Loading...

Webinar: Using HEOR Methods to Reduce Health Inequalities

2020-10-15T15:29:25-04:00Events|

Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.

(more…)

Webinar: Gene Therapies In Hemophilia

2020-10-15T15:28:22-04:00Events|

As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
(more…)

Webinar: Optimizing Product Launch Market Access strategy and Gross-to-Net Modeling

2020-08-21T07:20:56-04:00Events|

Join Precision and Akara Group on Thursday, 8/6, 2020 | 12:00 PM EDT – 1:00 PM EDT for a special live, online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.
(more…)

Circulating Tumor Cells Detected from Angiosarcoma Cancer Patients with use of ApoStream® Technology in a First-of-its-kind Study

2020-07-23T16:17:10-04:00Events, Thought Leadership|

PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA

HOUSTON, TX – November 14, 2018 – Precision for Medicine and TRACON Pharmaceuticals (NASDAQ:TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell’s proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study, titled Detection of Endoglin-Expressing CTCs in Patients Enrolled in an Adaptive Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), is the first of its kind to show the detection and capture of CTCs from angiosarcoma cancer patients. Interim study results were presented at the Connective Tissue Oncology Society (CTOS) annual meeting in Rome, Italy. (more…)

New FDA HCEI and PIE Guidelines Released: Are You Prepared? Sign up for our Free, Live Webinar Today!

2020-07-23T16:17:10-04:00Events, News|

On Wednesday, September 26th at 10:00am PDT/1:00pm EDT please join us for a special, live webinar:

Navigating the FDA’s Final Guidance on HCEI and PIE:
Value Communication That Works 

Presented by:

Ross Maclean, MD, PhD
Vice President,
Head of Medical Affairs
Ami Gopalan, PharmD, MBA
Vice President, Director,
Payer Access Solutions

(more…)

Load More Posts